Rim S. Kim

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S. Kim et al. · npj Breast Cancer · 2020 · 206 citations · Full text

Medicine, Oncology, Pathology +16

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

Rim S. Kim, Nan Song, Patrick G. Gavin et al. · JNCI Journal of the National Cancer Institute · 2019 · 55 citations · Full text

Medicine, Immunology, Oncology +17

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Samuel A. Jacobs, André Robidoux, Jame Abraham et al. · Breast Cancer Research · 2019 · 45 citations · Full text

Medicine, Oncology, Pharmacology +15

Neratinib-Plus-Cetuximab in Quadruple-WT ( <i>KRAS, NRAS, BRAF, PIK3CA</i> ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Samuel A. Jacobs, James J. Lee, Thomas J. George et al. · Clinical Cancer Research · 2020 · 26 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer

Lujia Chen, Ying Wang, Chunhui Cai et al. · Journal of Clinical Oncology · 2024 · 18 citations · Full text

Medicine, Oncology, Pharmacology +17